Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX001 in Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease
NCT05477563Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Jun 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
- Countries
- 4
01
Overview
A Phase 3 trial of exagamglogene autotemcel in beta thalassemia, sickle cell disease (SCD), sponsored by Vertex Pharmaceuticals. Started Aug 2022; status: recruiting.
02
Drugs
exagamglogene autotemcel
03
Conditions
beta thalassemiasickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05477563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477563.